Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:IRWD News 2 January 2026 - 5 January 2026

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

NEW YORK, Jan 5, 2026, 06:09 ET — Premarket Ironwood Pharmaceuticals shares rose about 1% in premarket trading on Monday after Citizens upgraded the gastrointestinal drugmaker, arguing that pricing pressure on Linzess has eased. Citizens analyst Jason Butler wrote that “LINZESS headwinds have passed” as the stock traded at $4.32 at 6:01 a.m. ET; Wells Fargo also lifted its price target to $5 from $3. The shares closed up 26.7% on Friday at $4.27. Investing The broker moves follow Ironwood’s 2026 outlook built on Linzess, its bowel-disorder franchise sold in a U.S. collaboration with AbbVie. Ironwood on Friday forecast 2026
5 January 2026
·····
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

NEW YORK, Jan 4, 2026, 13:54 ET — Market closed Ironwood Pharmaceuticals shares jumped 26.7% on Friday to close at $4.27, outpacing the broader healthcare stock complex after the company laid out a sharply higher 2026 outlook tied to its Linzess constipation drug. Investing The move matters because Ironwood is trying to prove it can generate steady cash flow from a single commercial asset while it works through a strategic review and prepares a key late-stage study for its pipeline drug apraglutide. SEC It also lands at a sensitive moment for U.S. drug pricing, where headline list-price cuts do not
4 January 2026
·····
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

NEW YORK, Jan 2, 2026, 14:08 ET — Regular session AbbVie shares ticked higher on Friday after Ironwood Pharmaceuticals, its partner on constipation drug Linzess, raised its 2026 outlook and said it lowered the medicine’s list price at the start of the year. The update matters because Linzess is co-developed and co-commercialized with AbbVie in the U.S., and changes in pricing can shift how much revenue is left after rebates and discounts. It also lands as investors reopen the books for 2026 with drug pricing back on the agenda and macro data next week expected to reset interest-rate bets, a
2 January 2026
·····

Stock Market Today

Glencore share price steadies after Rio Tinto walks away — what to watch next week

Glencore share price steadies after Rio Tinto walks away — what to watch next week

7 February 2026
Glencore shares closed up 0.6% at 478.1 pence Friday, rebounding after a 7% drop following the collapse of merger talks with Rio Tinto. The company is expected to announce the sale of its Kazzinc stake soon and has signed a non-binding agreement with Orion for a potential $9 billion deal in the DRC. Investors await Glencore’s full-year results on Feb. 18 for further guidance.
RELX share price slides again as AI fears linger, results next week in focus

RELX share price slides again as AI fears linger, results next week in focus

7 February 2026
RELX closed down 4.6% at 2,145 pence in London on Friday, capping a volatile week ahead of its Feb. 12 full-year results. The company bought back 465,361 shares even as selling continued amid investor concerns over AI risks and pricing power. Peers Wolters Kluwer and Thomson Reuters also faced pressure. Markets await RELX’s outlook for 2026 trading.
Go toTop